Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Marcucci

Showing results (141-150 of 536) with videos related to

Pageof 54
Sort By:
Aging|July 30, 2020
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AMLFeiteng Huang, Jie Sun, Wei Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2005
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell linesJim J Xiao, Ying Huang, Zunyan Dai, et al.
Leukemia Research|August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone, Barry Moser, Ben Sanford, et al.
Blood|February 23, 2008
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphomaLuca Paoluzzi, Mithat Gonen, Jeffrey R Gardner, et al.
International Journal of Molecular Sciences|June 24, 2022
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 ActivationDinh Hoa Hoang, Ralf Buettner, Melissa Valerio, et al.
Blood|November 19, 2005
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translationMario Notari, Paolo Neviani, Ramasamy Santhanam, et al.
Cancers|January 10, 2026
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation TrialShivani Handa, Kristin Koenig, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani, Don M Benson, Craig C Hofmeister, et al.
Blood|June 9, 2012
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Caroline Na, et al.
Haematologica|October 15, 2020
Exosomes-driven lipolysis and bone marrow niche remodeling supports leukemia expansionBijender Kumar, Marvin Orellana, Jamison Brooks, et al.
Pageof 54

Showing results (141-150 of 536) with videos related to

Sort By:
Pageof 54
Aging|July 30, 2020
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AMLFeiteng Huang, Jie Sun, Wei Chen, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2005
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell linesJim J Xiao, Ying Huang, Zunyan Dai, et al.
Leukemia Research|August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone, Barry Moser, Ben Sanford, et al.
Blood|February 23, 2008
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphomaLuca Paoluzzi, Mithat Gonen, Jeffrey R Gardner, et al.
International Journal of Molecular Sciences|June 24, 2022
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 ActivationDinh Hoa Hoang, Ralf Buettner, Melissa Valerio, et al.
Blood|November 19, 2005
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translationMario Notari, Paolo Neviani, Ramasamy Santhanam, et al.
Cancers|January 10, 2026
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation TrialShivani Handa, Kristin Koenig, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2009
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani, Don M Benson, Craig C Hofmeister, et al.
Blood|June 9, 2012
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemiaParvathi Ranganathan, Xueyan Yu, Caroline Na, et al.
Haematologica|October 15, 2020
Exosomes-driven lipolysis and bone marrow niche remodeling supports leukemia expansionBijender Kumar, Marvin Orellana, Jamison Brooks, et al.
Pageof 54